Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood clot gel vs tooth protein: which fixes gum bones better?

NCT ID NCT07183631

Disease control Sponsor: Semmelweis University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested two treatments for deep gum bone defects caused by periodontitis: platelet-rich fibrin (PRF), made from the patient's own blood, and enamel matrix derivative (EMD), a protein gel. Twenty-six patients received one of the treatments after surgery, and their gum health was checked at 6 months and 3 years. The goal was to see which approach better improves gum attachment and reduces pocket depth.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
platelet-rich fibrin (PRF) and enamel matrix derivative (EMD)
What this could lead to
If PRF works as well as EMD, it could offer a simpler, cheaper option for repairing gum bone damage from periodontitis.
What could go wrong
This is a small, completed Phase 4 trial with only 28 participants, so results may not apply to everyone. Both treatments are already used, so no major breakthrough is expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

28 people

The number who actually took part.

Started

Sep 2021

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. No systemic conditions affecting treatment outcomes 2. Good oral hygiene \[plaque index (PI) \<1; Löe 1967\] 3. Compliance with the maintenance program 4. Presence of at least one intra-bony defect with a probing depth (PD) of ≥6 mm and an intra-bony component of ≥3 mm confirmed by radiographs. Exclusion Criteria: * significant medical conditions: irradiation in the maxillofacial area, uncontrolled diabetes or hypertension, systemic steroid or bisphosphonate treatment, pregnancy, or lactation, infectious diseases, * age \<18 years, (3) smokers (\>5 cigarettes/day), * high residual inflammation (FMBS \>25%), * poor oral hygiene (FMPS \>25%), and * defect-related factors: furcation involvement, endo-perio defects, horizontal defects, or multi-tooth defects .

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced chronic periodontitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alveolar Bone Loss chronic periodontitis periodontal disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Periodontal bone loss Periodontal disease Platelet rich fibrin

Contacts and locations

Locations

  • Semmelweis University

    Budapest, 1088, Hungary

More trials for these conditions

Other studies related to the condition(s) this trial covers.